Clinical effects of uterine artery embolization combined with Mifepristone and Ethacridine Lactate in induction of labor for placenta previa

Abstract Objective To investigate the clinical efficacy of uterine artery embolization combined with mifepristone and levonorgestrel in the induction of labor for placenta previa. Methods A total of 108 high-risk pregnant women with placenta previa who underwent induction of labor were enrolled in this study from January 2018 to June 2022. They were randomly divided into two groups: the intervention group (n = 51) received uterine artery embolization combined with mifepristone and levonorgestrel amniocentesis injection for induction of labor, while the control group (n = 57) received oral mifepristone and levonorgestrel amniocentesis injection for induction of labor as a comparison. The induction time, blood loss during and after induction, and complications were compared between the two groups. Throughout the study, all procedures adhered strictly to the ethical principles outlined in the Helsinki Declaration. No intervention-related complications occurred during the follow-up period. Results Among the 57 cases in the control group, 55 cases (96.49%) delivered vaginally, 25 cases (43.85%) had postpartum hemorrhage, and 2 cases (3.50%) underwent emergency cesarean section due to bleeding volume reaching 1000 ml. All 51 cases (100%) in the intervention group delivered vaginally, and 6 cases had postpartum hemorrhage. The induction time in the control group was (25.296 ± 1.6303), while the induction time in the intervention group was (21.753 ± 0.5334), and the difference was statistically significant (P < 0.01). The total hospital stay after induction of labor in the control group was (5.767 ± 1.2977), while the total hospital stay after induction of labor in the intervention group was (4.169 ± 0.5771), and the difference was statistically significant (P < 0.01). Conclusion In placenta previa induction of labor, uterine artery embolization combined with mifepristone and levonorgestrel can effectively reduce blood loss during induction, shorten induction duration, improve induction success rate, and reduce the risk of cesarean section during induction. It can also protect the uterus and prevent placental adhesion, ensuring the safety of pregnant women. It is a safe, minimally invasive, and effective method that deserves clinical promotion.